2022年8月5日 · Vixarelimab treatment improved sleep, as evidenced by significantly greater changes from baseline in sleep loss VAS compared with placebo, and by more patients achieving ≥4-point reduction in weekly average sleep quality NRS at various time points.

2023年2月3日 · Vixarelimab, a human monoclonal antibody, binds to the beta subunit of the oncostatin M receptor, inhibiting signalling of both interleukin 31 and oncostatin M, two cytokine pathways that contribute to pruritus and nodule formation in prurigo nodularis.

Vixarelimab is an investigational fully human monoclonal antibody that targets oncostatin M receptor beta (OSMRβ), which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation, and fibrosis.

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

2023年12月8日 · The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.

Vixarelimab Phase 2 Therapeutic Area Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by severely pruritic skin nodules. Mechanism of Action Monoclonal antibody inhibiting signaling through oncostatin M receptor beta (OSMRβ). • Vixarelimab inhibits signaling of interleukin-31 (IL-31) and oncostatin M (OSM), 2 key

Vixarelimab (KPL-716; Kiniksa Pharmaceuticals) is a first-in-class fully human monoclonal antibody that is under investigation for the treatment of prurigo nod-ularis. Vixarelimab targets OSMRβ, a cell surface re-ceptor that differentially heterodimerizes with the IL-31 receptor α (IL-31Rα) chain to form the IL-31 receptor

Vixarelimab DrugBank Accession Number DB16350 Background. Vixarelimab is under investigation in clinical trial NCT03816891 (A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Prurigo Nodularis). Type Biotech Groups Investigational Synonyms

Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash.

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD).